Uppsala, January 23, 2019. Biovica will present at Stora Aktiedagen focused on Life Science, a small-cap investor conference, held on January 29, 2019 at Medicon Village, Scheelevägen 2 in Lund. The event is arranged by Aktiespararna and the company will be represented by CEO Anders Rylander 12.50 CET.
For full program and registration, see link https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-29-januari-0
Anders Rylander, CEO Biovica.
Phone: +46 (0)18 444 48 35,
In the event of contradictions or differences between the Swedish press release and this English translation of the Swedish press release, the Swedish text shall be given priority.
Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.
Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB, firstname.lastname@example.org, +46 8 528 00 399.
Read more: www.biovica.com